1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Want To Promote Off-Label? Pick Your Battlefield

 
• By Donna Young

US drug makers everywhere owe Amarin Pharmaceuticals a big pat on the back for challenging the FDA's threats of bringing misbranding actions against manufacturers that seek to promote their drugs for off-label uses, said Philadelphia lawyer James Beck, counsel in the life sciences industry group at Reed Smith.

US drug makers everywhere owe Amarin Pharmaceuticals a big pat on the back for challenging the FDA's threats of bringing misbranding actions against manufacturers that seek to promote their drugs for off-label uses, said Philadelphia lawyer James Beck, counsel in the life sciences industry group at Reed Smith.

Amarin's win on Aug. 7 in convincing a federal judge in New York to permit the firm to share "truthful...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

More from Therapy Areas